Tradition Wealth Management LLC Trims Stake in Eli Lilly and Company $LLY

Tradition Wealth Management LLC reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,357 shares of the company’s stock after selling 15 shares during the quarter. Tradition Wealth Management LLC’s holdings in Eli Lilly and Company were worth $1,121,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of LLY. PNC Financial Services Group Inc. increased its position in shares of Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after buying an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after buying an additional 4,975,395 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Eli Lilly and Company by 103,831.6% in the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company’s stock valued at $12,278,292,000 after buying an additional 14,852,076 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock valued at $10,495,261,000 after buying an additional 81,587 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Eli Lilly and Company by 14.6% in the fourth quarter. Northern Trust Corp now owns 9,448,219 shares of the company’s stock valued at $7,294,025,000 after buying an additional 1,204,337 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $704.7540 on Thursday. The stock’s fifty day moving average is $758.91 and its two-hundred day moving average is $792.41. The firm has a market capitalization of $667.02 billion, a P/E ratio of 46.06, a price-to-earnings-growth ratio of 0.98 and a beta of 0.44. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.9%. Eli Lilly and Company’s payout ratio is 39.22%.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of recent analyst reports. Leerink Partners restated a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. HSBC lowered Eli Lilly and Company from a “buy” rating to a “reduce” rating and lowered their price target for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Guggenheim lowered their price target on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a research note on Wednesday, August 13th. Finally, Cantor Fitzgerald lowered their price target on Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $950.17.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.